Cargando…

Dry eye, sleep quality, and mood status in glaucoma patients receiving prostaglandin monotherapy were comparable with those in non-glaucoma subjects

PURPOSE: Prior studies suggested that glaucoma patients suffer worse dry eye and mood and sleep disorders than non-glaucoma subjects. Prostaglandin analogues are first-line therapy for glaucoma, inducing few instillation problems and sufficient pressure-reduction effects. This study compared dry eye...

Descripción completa

Detalles Bibliográficos
Autores principales: Ra, Shugyoku, Ayaki, Masahiko, Yuki, Kenya, Tsubota, Kazuo, Negishi, Kazuno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703517/
https://www.ncbi.nlm.nih.gov/pubmed/29176799
http://dx.doi.org/10.1371/journal.pone.0188534
_version_ 1783281695634489344
author Ra, Shugyoku
Ayaki, Masahiko
Yuki, Kenya
Tsubota, Kazuo
Negishi, Kazuno
author_facet Ra, Shugyoku
Ayaki, Masahiko
Yuki, Kenya
Tsubota, Kazuo
Negishi, Kazuno
author_sort Ra, Shugyoku
collection PubMed
description PURPOSE: Prior studies suggested that glaucoma patients suffer worse dry eye and mood and sleep disorders than non-glaucoma subjects. Prostaglandin analogues are first-line therapy for glaucoma, inducing few instillation problems and sufficient pressure-reduction effects. This study compared dry eye, sleep quality, and mood status between glaucoma patients receiving prostaglandin monotherapy and non-glaucoma subjects. METHODS: This cross-sectional study evaluated 1520 patients (579 males and 941 females) for glaucoma status and dry eye-related symptoms (dryness, eye fatigue, photophobia, pain, blurring) and signs (Schirmer test, tear break-up time, corneal staining scores). Of the total cohort, 93 patients were also evaluated by Pittsburgh sleep quality index (PSQI) and hospital anxiety and depression score (HADS). Inclusion criteria were consecutive patients ≥ 51 years of age and best-corrected visual acuity ≥ 20/25. Glaucoma patients included those treated with prostaglandin or a fixed combination including prostaglandin. Exclusion criteria were history of ocular surgery within one month. Data were analyzed using the chi-square or Mann-Whitney U tests, at 5% significance. RESULTS: There were no significant differences in dry eye-related signs and symptoms between the control (n = 1431, mean age of 66.9 years) and glaucoma groups (n = 89, 67.9 years). The psychiatric sub-analysis of the control (n = 61, 66.2 years) and glaucoma groups (n = 32, 67.3 years) revealed mean scores of 5.02 ± 3.10 and 5.16 ± 3.46 for PSQI (normal range ≤ 5), 9.47 ± 5.61 and 9.42 ± 7.36 for HADS (normal range ≤ 10), 4.84 ± 3.22 and 4.71 ± 3.45 for anxiety (normal range ≤ 5), and 4.63 ± 3.05 and 4.71 ± 4.40 for depression (normal range ≤ 5), respectively, without statistical significance. CONCLUSIONS: Our results were comparable between glaucoma patients on prostaglandin monotherapy and non-glaucoma subjects for dry eye-related clinical manifestations, sleep quality, and mood status.
format Online
Article
Text
id pubmed-5703517
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-57035172017-12-08 Dry eye, sleep quality, and mood status in glaucoma patients receiving prostaglandin monotherapy were comparable with those in non-glaucoma subjects Ra, Shugyoku Ayaki, Masahiko Yuki, Kenya Tsubota, Kazuo Negishi, Kazuno PLoS One Research Article PURPOSE: Prior studies suggested that glaucoma patients suffer worse dry eye and mood and sleep disorders than non-glaucoma subjects. Prostaglandin analogues are first-line therapy for glaucoma, inducing few instillation problems and sufficient pressure-reduction effects. This study compared dry eye, sleep quality, and mood status between glaucoma patients receiving prostaglandin monotherapy and non-glaucoma subjects. METHODS: This cross-sectional study evaluated 1520 patients (579 males and 941 females) for glaucoma status and dry eye-related symptoms (dryness, eye fatigue, photophobia, pain, blurring) and signs (Schirmer test, tear break-up time, corneal staining scores). Of the total cohort, 93 patients were also evaluated by Pittsburgh sleep quality index (PSQI) and hospital anxiety and depression score (HADS). Inclusion criteria were consecutive patients ≥ 51 years of age and best-corrected visual acuity ≥ 20/25. Glaucoma patients included those treated with prostaglandin or a fixed combination including prostaglandin. Exclusion criteria were history of ocular surgery within one month. Data were analyzed using the chi-square or Mann-Whitney U tests, at 5% significance. RESULTS: There were no significant differences in dry eye-related signs and symptoms between the control (n = 1431, mean age of 66.9 years) and glaucoma groups (n = 89, 67.9 years). The psychiatric sub-analysis of the control (n = 61, 66.2 years) and glaucoma groups (n = 32, 67.3 years) revealed mean scores of 5.02 ± 3.10 and 5.16 ± 3.46 for PSQI (normal range ≤ 5), 9.47 ± 5.61 and 9.42 ± 7.36 for HADS (normal range ≤ 10), 4.84 ± 3.22 and 4.71 ± 3.45 for anxiety (normal range ≤ 5), and 4.63 ± 3.05 and 4.71 ± 4.40 for depression (normal range ≤ 5), respectively, without statistical significance. CONCLUSIONS: Our results were comparable between glaucoma patients on prostaglandin monotherapy and non-glaucoma subjects for dry eye-related clinical manifestations, sleep quality, and mood status. Public Library of Science 2017-11-27 /pmc/articles/PMC5703517/ /pubmed/29176799 http://dx.doi.org/10.1371/journal.pone.0188534 Text en © 2017 Ra et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Ra, Shugyoku
Ayaki, Masahiko
Yuki, Kenya
Tsubota, Kazuo
Negishi, Kazuno
Dry eye, sleep quality, and mood status in glaucoma patients receiving prostaglandin monotherapy were comparable with those in non-glaucoma subjects
title Dry eye, sleep quality, and mood status in glaucoma patients receiving prostaglandin monotherapy were comparable with those in non-glaucoma subjects
title_full Dry eye, sleep quality, and mood status in glaucoma patients receiving prostaglandin monotherapy were comparable with those in non-glaucoma subjects
title_fullStr Dry eye, sleep quality, and mood status in glaucoma patients receiving prostaglandin monotherapy were comparable with those in non-glaucoma subjects
title_full_unstemmed Dry eye, sleep quality, and mood status in glaucoma patients receiving prostaglandin monotherapy were comparable with those in non-glaucoma subjects
title_short Dry eye, sleep quality, and mood status in glaucoma patients receiving prostaglandin monotherapy were comparable with those in non-glaucoma subjects
title_sort dry eye, sleep quality, and mood status in glaucoma patients receiving prostaglandin monotherapy were comparable with those in non-glaucoma subjects
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703517/
https://www.ncbi.nlm.nih.gov/pubmed/29176799
http://dx.doi.org/10.1371/journal.pone.0188534
work_keys_str_mv AT rashugyoku dryeyesleepqualityandmoodstatusinglaucomapatientsreceivingprostaglandinmonotherapywerecomparablewiththoseinnonglaucomasubjects
AT ayakimasahiko dryeyesleepqualityandmoodstatusinglaucomapatientsreceivingprostaglandinmonotherapywerecomparablewiththoseinnonglaucomasubjects
AT yukikenya dryeyesleepqualityandmoodstatusinglaucomapatientsreceivingprostaglandinmonotherapywerecomparablewiththoseinnonglaucomasubjects
AT tsubotakazuo dryeyesleepqualityandmoodstatusinglaucomapatientsreceivingprostaglandinmonotherapywerecomparablewiththoseinnonglaucomasubjects
AT negishikazuno dryeyesleepqualityandmoodstatusinglaucomapatientsreceivingprostaglandinmonotherapywerecomparablewiththoseinnonglaucomasubjects